The results of the survival analysis demonstrated that increased expression of DCTN2 was linked to reduced overall survival rates across multiple cancer types, such as bladder cancer, kidney renal clear cell carcinoma and liver hepatocellular carcinoma (LIHC) (Figure 1D,E). This evidence concerns the gene DCTN2 and urinary bladder carcinoma.